...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
【24h】

In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.

机译:新型选择性α7神经元烟碱乙酰胆碱受体激动剂ABT-107的体外药理学表征。

获取原文
获取原文并翻译 | 示例

摘要

Enhancement of alpha7 nicotinic acetylcholine receptor (nAChR) activity is considered a therapeutic approach for ameliorating cognitive deficits present in Alzheimer's disease and schizophrenia. In this study, we describe the in vitro profile of a novel selective alpha7 nAChR agonist, 5-(6-[(3R)-1-azabicyclo[2,2,2]oct-3-yloxy]pyridazin-3-yl)-1H-indole (ABT-107). ABT-107 displayed high affinity binding to alpha7 nAChRs [rat or human cortex, [(3)H](1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1 ]heptane (A-585539), K(i) = 0.2-0.6 nM or [(3)H]methyllycaconitine (MLA), 7 nM] that was at least 100-fold selective versus non-alpha7 nAChRs and other receptors. Functionally, ABT-107 did not evoke detectible currents in Xenopus oocytes expressing human or nonhuman alpha3beta4, chimeric (alpha6/alpha3)beta4, or 5-HT(3A) receptors, and weak or negligible Ca(2+) responses in human neuroblastoma IMR-32 cells (alpha3* function) and human alpha4beta2 and alpha4beta4 nAChRs expressed in human embryonic kidney 293 cells. ABT-107 potently evoked human and rat alpha7 nAChR current responses in oocytes (EC(50), 50-90 nM total charge, approximately 80% normalized to acetylcholine) that were enhanced by the positive allosteric modulator (PAM) 4-[5-(4-chloro-phenyl)-2-methyl-3-propionyl-pyrrol-1-yl]-benzenesulfonamide (A-867744). In rat hippocampus, ABT-107 alone evoked alpha7-like currents, which were inhibited by the alpha7 antagonist MLA. In dentate gyrus granule cells, ABT-107 enhanced spontaneous inhibitory postsynaptic current activity when coapplied with A-867744. In the presence of an alpha7 PAM [A-867744 or N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride (PNU-120596)], the addition of ABT-107 elicited MLA-sensitive alpha7 nAChR-mediated Ca(2+) signals in IMR-32 cells and rat cortical cultures and enhanced extracellular signal-regulated kinase phosphorylation in differentiated PC-12 cells. ABT-107 was also effective in protecting rat cortical cultures against glutamate-induced toxicity. In summary, ABT-107 is a selective high affinity alpha7 nAChR agonist suitable for characterizing the roles of this subtype in pharmacological studies.
机译:增强α7烟碱乙酰胆碱受体(nAChR)活性被认为是缓解阿尔茨海默氏病和精神分裂症中存在的认知缺陷的治疗方法。在这项研究中,我们描述了新型的选择性α7nAChR激动剂5-(6-[(3R)-1-azabicyclo [2,2,2] oct-3-yloxy] pyazazin-3-yl)的体外概况-1H-吲哚(ABT-107)。 ABT-107对α7nAChRs [大鼠或人皮质,[(3)H](1S,4S)-2,2-二甲基-5-(6-苯基吡啶并-3-基)-5-氮杂- 2-氮杂双环[2.2.1]庚烷(A-585539),K(i)= 0.2-0.6 nM或[(3)H]甲基lycaconitine(MLA),7 nM]与非alpha7 nAChRs和其他受体。在功能上,ABT-107不会在表达人类或非人类alpha3beta4,嵌合(alpha6 / alpha3)beta4或5-HT(3A)受体以及人类神经母细胞瘤IMR中弱或可忽略的Ca(2+)反应的爪蟾卵母细胞中引起可检测电流-32细胞(alpha3 *功能)以及在人胚胎肾脏293细胞中表达的人alpha4beta2和alpha4beta4 nAChRs。 ABT-107在卵母细胞(EC(50),总电荷为50-90 nM,约80%标准化为乙酰胆碱)中强烈诱发了人和大鼠alpha7 nAChR的电流响应,而正变构调节剂(PAM)4- [5-] (4-氯-苯基)-2-甲基-3-丙酰基-吡咯-1-基]-苯磺酰胺(A-867744)。在大鼠海马中,单独的ABT-107引起了alpha7样电流,该电流被alpha7拮抗剂MLA抑制。在齿状回颗粒细胞中,当与A-867744共同使用时,ABT-107增强了自发抑制突触后电流的活性。在存在alpha7 PAM [A-867744或N-[(3R)-1-氮杂双环[2.2.2]辛-3-基] -4-氯苯甲酰胺盐酸盐(PNU-120596)]的情况下,添加ABT- 107在IMR-32细胞和大鼠皮质培养物中引发MLA敏感alpha7 nAChR介导的Ca(2+)信号,并在分化的PC-12细胞中增强细胞外信号调节的激酶磷酸化。 ABT-107还可有效保护大鼠皮质培养物免受谷氨酸诱导的毒性。总之,ABT-107是一种选择性的高亲和力α7nAChR激动剂,适用于表征该亚型在药理学研究中的作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号